SELLAS Life Sciences Adds Once-a-Week Dose Cohort in Ongoing Phase 1 Clinical Trial with its Highly Selective CDK9 Inhibitor GFH009
07.07.2022 - The Company Continues to Evaluate Optimal Dosing for Patients with Acute Myeloid Leukemia and Lymphoma in Preparation for Phase 2NEW YORK, July 07, 2022 (GLOBE NEWSWIRE) - SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), ... Seite 1
United States Dragan Cicic Life Sciences Group Inc Clinical Development Company Continues Evaluate Optimal Dosing
Source: wallstreet-online.de